{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:37:38Z","timestamp":1793363858133,"version":"4.5.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,20]]},"DOI":"10.18632\/oncotarget.5320","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"33165-33177","source":"Crossref","is-referenced-by-count":112,"title":["Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer"],"prefix":"10.18632","volume":"6","author":[{"given":"Manish R.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Drees","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogeng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Prigge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Dash","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Kratzke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mesev","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Etchison","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Federspiel","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Department of Molecular Medicine, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Department of Molecular Medicine, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kratzke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,28]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.trsl.2012.12.010","article-title":"Oncolytic virus therapy for cancer: the first wave of translational clinical trials","volume":"161","author":"Kratzke","year":"2013","journal-title":"Transl Res"},{"key":"2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Bell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ijc.20276","article-title":"Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer","volume":"112","author":"Luo","year":"2004","journal-title":"Int J Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"5","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma","volume":"69","author":"Vile","year":"2009","journal-title":"Cancer research"},{"key":"6","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Barber","year":"2003","journal-title":"Journal of virology"},{"key":"7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2009.111","article-title":"Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates","volume":"21","author":"Meier","year":"2010","journal-title":"Hum Gene Ther"},{"key":"8","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3390\/v1030832","article-title":"Interferon response and viral evasion by members of the family rhabdoviridae","volume":"1","author":"Schnell","year":"2009","journal-title":"Viruses"},{"key":"9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Durbin","year":"2003","journal-title":"Cancer Cell"},{"key":"10","first-page":"1541","article-title":"Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells","volume":"15","author":"Park","year":"2006","journal-title":"Oncol Rep"},{"key":"11","first-page":"277","article-title":"PKR in innate immunity, cancer, and viral oncolysis","volume":"383","author":"Barber","year":"2007","journal-title":"Methods Mol Biol"},{"key":"12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(03)00330-1","article-title":"Defective translational control facilitates vesicular stomatitis virus oncolysis","volume":"5","author":"Barber","year":"2004","journal-title":"Cancer Cell"},{"key":"13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccr.2011.09.005","article-title":"Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death","volume":"20","author":"Mamai","year":"2011","journal-title":"Cancer Cell"},{"key":"14","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1128\/JVI.75.7.3474-3479.2001","article-title":"Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis","volume":"75","author":"Barber","year":"2001","journal-title":"J Virol"},{"key":"15","doi-asserted-by":"crossref","first-page":"10177","DOI":"10.1128\/JVI.76.20.10177-10187.2002","article-title":"Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1","volume":"76","author":"Lyles","year":"2002","journal-title":"J Virol"},{"key":"16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(97)00108-X","article-title":"Mouse lung epithelial cell lines\u2014tools for the study of differentiation and the neoplastic phenotype","volume":"123","author":"Dinsdale","year":"1997","journal-title":"Toxicology"},{"key":"17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cgt.2012.14","article-title":"Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta","volume":"19","author":"Russell","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"18","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","article-title":"Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus","volume":"67","author":"Vile","year":"2007","journal-title":"Cancer research"},{"key":"19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/mt.2010.224","article-title":"Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide","volume":"19","author":"Vile","year":"2011","journal-title":"Mol Ther"},{"key":"20","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","article-title":"Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells","volume":"188","author":"Klinman","year":"2012","journal-title":"J Immunol"},{"key":"21","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.4049\/jimmunol.179.8.5228","article-title":"CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis","volume":"179","author":"Khoury","year":"2007","journal-title":"J Immunol"},{"key":"22","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","article-title":"Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells","volume":"162","author":"Mescher","year":"1999","journal-title":"J Immunol"},{"key":"23","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation","volume":"174","author":"Mescher","year":"2005","journal-title":"J Immunol"},{"key":"24","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.4049\/jimmunol.169.12.6842","article-title":"The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells","volume":"169","author":"Mescher","year":"2002","journal-title":"J Immunol"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Rizvi, Garon, Patnaik, Gandhi, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting. 2014; 2.","DOI":"10.1200\/jco.2014.32.15_suppl.8007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Rizvi, Chow, Dirix, Gettinger, Gordon. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting. 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.tps8123"},{"key":"27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Gandara","year":"2015","journal-title":"The Lancet Oncology"},{"key":"28","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer","volume":"372","author":"Felip","year":"2015","journal-title":"N Engl J Med"},{"key":"29","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Anders","year":"2014","journal-title":"Clin Cancer Res"},{"key":"30","first-page":"22ra232","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Allison","year":"2014","journal-title":"Science translational medicine"},{"key":"31","doi-asserted-by":"crossref","first-page":"e28683","DOI":"10.1371\/journal.pone.0028683","article-title":"Epigenetic silencing of IRF7 and\/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses","volume":"6","author":"Tainsky","year":"2011","journal-title":"PLoS One"},{"key":"32","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1371\/journal.pone.0001927","article-title":"Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients","volume":"3","author":"Verweij","year":"2008","journal-title":"PLoS One"},{"key":"33","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/JVI.00074-14","article-title":"Vesiculovirus neutralization by natural IgM and complement","volume":"88","author":"Russell","year":"2014","journal-title":"J Virol"},{"key":"34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/gt.2012.31","article-title":"Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses","volume":"20","author":"Russell","year":"2013","journal-title":"Gene Ther"},{"key":"35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mt.6300039","article-title":"Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity","volume":"15","author":"Bell","year":"2007","journal-title":"Mol Ther"},{"key":"36","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Guthrie","year":"2015","journal-title":"J Clin Oncol"},{"key":"37","volume-title":"Virus isolation and quantification","author":"Hierholzer JCaK","year":"1996"},{"key":"38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-61779-340-0_10","article-title":"Propagation, purification, andtesting of oncolytic vesicular stomatitis virus strains","volume":"797","author":"Bell","year":"2012","journal-title":"Methods Mol Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:41:39Z","timestamp":1692038499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,28]]},"references-count":38,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2015,10,20]]}},"alternative-id":["5320","26431376"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5320","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,28]]}}}